The Role of Brain Natriuretic Peptide as a Prognostic Marker for Sepsis

Binita Bhandari 1, Jessica Cunningham 1

1. Internal Medicine, University of Pittsburgh Medical Center (UPMC) Pinnacle, Harrisburg, USA

Corresponding author: Binita Bhandari, bhandarib@upmc.edu

Abstract

Brain natriuretic peptide (BNP) is a neurohormone released in response to volume expansion and increased pressure. It is commonly used to assist in the diagnosis and management of heart failure. BNP can also play an important role as a biomarker in septic shock; however, elevations of BNP in conditions other than sepsis or cardiac dysfunction limits its use as the sole prognostic marker in patients hospitalized with sepsis. Further relationships regarding laboratory value and correlation with severity of illness need to be established with larger prospective studies to develop consensus regarding a cut-off point for optimum sensitivity and specificity in predicting in-hospital mortality related to sepsis.

Introduction And Background

Natriuretic peptides are peptide hormones mostly released by the heart muscles in response to increased volume status and wall stress, which are key elements in cardiovascular physiology [1]. Brain natriuretic peptide (BNP) is a commonly measured natriuretic peptide, which is released in conditions that leads to volume expansion and increased myocardial wall pressure. The physiological functions of BNP include relaxation of vasomotor tone, inhibition of sympathetic activity, reduction in cardiac preload, increase in renal blood flow, and increase in natriuresis and diuresis [2].

Plasma BNP has become an important tool in clinical decision-making regarding diagnosis, management, and risk stratification of heart failure [3,4]. In addition to heart failure, it has also been studied in angina, pericarditis, and various non-cardiovascular conditions such as renal failure, hyperthyroidism, pulmonary embolism, anemia, and post-surgery [5-8]. Plasma BNP and N-terminal pro brain natriuretic peptide (NT-proBNP) are viewed as comparable in terms of the diagnosis, evaluation, and monitoring of heart-failure patients [9].

Sepsis is an inflammatory response to an infection characterized by systemic inflammation and life-threatening organ dysfunction [10]. It is a major cause of hospitalization and critical care admissions and is associated with a significant healthcare burden globally. In 2017, the new incidence of sepsis was estimated at around 48.7 million cases worldwide with 11 million sepsis-related deaths representing one-fifth of all global deaths [11]. Data from an international audit of the intensive care unit (ICU) patients have shown hospital mortality rates of up to one-third of patients with sepsis [12]. In the US, the cost of sepsis-related in-patient hospital admissions for Medicare beneficiaries has been on the rise, with an increase in total expenditure from $17.8 billion to $22.4 billion between 2012 and 2018. Combined with subsequent skilled nursing facility admission, the total Medicare cost is estimated to be $41.5 billion [13]. Due to the critical nature of sepsis, the associated morbidity and mortality, and the resulting economic impact on healthcare, prompt recognition of the condition and enactment of early therapeutic interventions in severe sepsis and septic shock are important.

Review

Prospective studies have shown that plasma BNP concentration can reliably identify patients developing sepsis-induced myocardial depression [14]. There have been recent metanalyses looking at both BNP and NT-proBNP that have shown moderate predictive value for mortality in septic patients [15,16]. Larger prospective studies are required to establish further relationships regarding laboratory value and correlation with the severity of the illness to better identify a cut-off point for optimum sensitivity and specificity in predicting in-hospital mortality related to sepsis.

Patients with sepsis or septic shock have cardiovascular dysfunction. BNP is understood to be produced as a result of ventricular myocardial wall stretch, but other factors such as degree of inflammation, use of vasopressor medications as well as acute kidney injury may come into play in sepsis [17]. The primary mechanism for the elevation of BNP and NT-proBNP in critical sepsis remains uncertain.
Elevated BNP levels have been described even in the absence of demonstrable ventricular dysfunction and have been correlated with C-reactive protein levels [18], suggesting that the value may be an indicator of the severity of inflammation as well. Whether the mechanism for elevated BNP in critically ill patients with sepsis is solely due to cardiovascular insufficiency or is influenced by other factors, like systemic inflammation, remains unclear.

With regard to the correlation between plasma BNP levels and mortality, studies vary in terms of BNP cut-off levels and associated mortality. Charpentier et al. showed that BNP levels above 190 pg/ml in patients admitted with sepsis and septic shock were associated with a five-fold increase in the risk of death within 30 days [19]. Chen et al. used plasma BNP cut-off of 113 pg/ml in the emergency department, which independently predicted mortality in septic patients [20]. Perman et al. demonstrated a greater risk of mortality (11.6% vs 2.1%; p < 0.0001) and development of severe sepsis and septic shock with a lower cut-off level of 49 pg/ml [21].

Other studies have used higher cut-off values. For example, Papanikolaou et al. showed day-1 BNP of >800 pg/ml predicting mortality with area under the curve (AUC) value 0.7 (95% CI: 0.54-0.86) [22]. Similarly, Khoury et al. concluded that admission plasma BNP above 1,000 pg/ml independently predicted short- and long-term mortality in hospitalized patients with sepsis and septic shock [23]. The prognostic value of elevated BNP concentration regarding in-hospital mortality and length of hospital stay has been established regardless of the presence of cardiac dysfunction [24].

Conversely, some studies have failed to show a correlation between elevated BNP levels and mortality. Mclean et al. showed that BNP levels are elevated in sepsis and septic shock patients in the presence or absence of cardiac dysfunction; however, they did not show any prognostic significance of initial BNP levels or daily changes in BNP levels [25]. Cuthbertson et al. also showed elevated BNP levels in patients with sepsis and septic shock, but failed to show any predictive value in terms of mortality or outcome after intensive care [26].

Recent metanalyses looking at both BNP and NT-proBNP have shown moderate predictive value for mortality in septic patients [15,16]. Vallabhaidesyula et al. analyzed 35 studies (3,508 patients) and concluded that a cut-off level of plasma BNP of 633 pg/ml shows the greatest discrimination for mortality with an area under the curve (AUC) value of 0.766 (95% CI: 0.734-0.797) [16]. However, as the authors have pointed out, the heterogeneity of the included patient population means that these results are not applicable to all the patients admitted with sepsis and septic shock.

Conclusions

BNP can play an important role as a biomarker in septic shock; however, elevations of BNP in conditions other than sepsis or cardiac dysfunction limits its use as the sole prognostic marker in patients hospitalized with sepsis. BNP is relatively easy to obtain as a laboratory test and has the potential to identify patients with imminent cardiovascular compromise and those at high risk for mortality. Further relationships regarding laboratory value and correlation with severity of illness need to be established with larger prospective studies to develop consensus regarding a cut-off point for optimum sensitivity and specificity in predicting in-hospital mortality related to sepsis.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Okamoto R, Ali Y, Hashizume R, Suzuki N, Ito M: BNP as a major player in the heart-kidney connection. J Mol Sci. 2019, 20:5581. 10.5390/jms20145581
2. Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM: Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol. 2009, 191:541-366. 10.1007/978-3-540-68964-5_15
3. Ibrahim N, Januzzi JL: The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management. Expert Rev Cardiovasc Ther. 2015, 13:1017-1050. 10.1586/14779072.2015.1071664
4. Maisel AS, Duran JM, Wettersten N: Natriuretic peptides in heart failure: atrial and B-type natriuretic peptides. Heart Fail Clin. 2018, 14:13-25. 10.1016/j.hfc.2017.08.002
5. Ahmed W, Zafar S, Alam AY, Akhtar N, Shah MA, Alpert MA: Plasma levels of B-type natriuretic peptide in patients with unstable angina pectoris or acute myocardial infarction: prognostic significance and
therapeutic implications. Angiology. 2007, 58:269-274. 10.1177/0003519707302543
6. Rodscher RN, Biccard BM, Le Manach Y, et al.: The prognostic value of pre-operative and post-operative B-type natriuretic peptides in patients undergoing noncardiac surgery: B-type natriuretic peptide and N-terminal fragment of pro-B-type natriuretic peptide: a systematic review and individual patient data meta-analysis. J Am Coll Cardiol. 2014, 65:170-180. 10.1016/j.jacc.2013.08.1659
7. Cavallazzi R, Nair A, Vauz T, Marik PE: Natriuretic peptides in acute pulmonary embolism: a systematic review. Intensive Care Med. 2008, 34:2147-2156. 10.1007/s00134-008-1214-5
8. Ertugrul DT, Gursoy A, Sahin M, et al.: Evaluation of brain natriuretic peptide levels in hyperthyroidism and hypothyroidism. J Natl Med Assoc. 2008, 100:401-405. 10.1016/j.njm.2015.03.004
9. Farnsworth CW, Bailey AL, Jaffe AS, Scott MG: Diagnostic concordance between NT-proBNP and BNP for suspected heart failure. Clin Biochem. 2018, 59:50-55. 10.1016/j.clinbiochem.2018.07.002
10. Cecconi M, Evans L, Levy M, Rhodes A: Sepsis and septic shock. Lancet. 2018, 392:75-87. 10.1016/S0140-6756(18)30696-2
11. Rudd KE, Johnson SC, Agesa KM, et al.: Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020, 395:200-211. 10.1016/S0140-6756(19)32899-7
12. Vincent JL, Marshall JC, Namendys-Silva SA, et al.: Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit. Lancet Respir Med. 2014, 2:380-386. 10.1016/S2213-2600(14)7001-X
13. Buchman TG, Simpson SQ, Scharrett KL, et al.: Sepsis among Medicare beneficiaries: I. The burdens of sepsis, 2012-2018. Crit Care Med. 2020, 48:276-288. 10.1097/CCM.0000000000004224
14. Post F, Weitemann LS, Messow CM, Sinning C, Münzel T: Relationship between B-type natriuretic peptide and adverse outcome in patients with sepsis: a systematic review and meta-analysis. Mayo Clin Proc Innov Qual Outcomes. 2020, 4:50-64. 10.1016/j.mayocpiqo.2019.10.008
15. Wittbauer B, Busch C, Fraunberger P, et al.: Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med. 2005, 31:1696-1702. 10.1007/s00134-005-1910-0
16. Shor R, Rozenman Y, Bolshinsky A, et al.: BNP in septic patients without systolic myocardial dysfunction. Eur J Intern Med. 2006, 17:536-540. 10.1016/j.ejim.2006.07.013
17. Charpentier J, Luyt CE, Fulla Y, et al.: Prognostic significance of brain natriuretic peptide in non-cardiac patients with sepsis: a meta-analysis. J Crit Care. 2018, 48:145-152. 10.1016/j.jcrc.2018.08.040
18. Vallabhajosyula S, Wang Z, Murad MH, et al.: Prognostic value of increased plasma levels of brain natriuretic peptide in patients with clinical evidence of sepsis presenting to the emergency department. Crit Care Med. 2019, 47:10.1097/CCM.0000000000003750
19. Chen Y, Li C: Prognostic value of increased plasma levels of brain natriuretic peptide in non-cardiac patients with sepsis: a systematic review and meta-analysis. J Crit Care. 2014, 32:660-665. 10.1016/j.jcrc.2013.10.011
20. VallaBhajosyula S, Wang Z, Murad MH, et al.: Prognostic value of increased plasma levels of brain natriuretic peptide in patients with sepsis: a systematic review and meta-analysis. Mayo Clin Proc Innov Qual Outcomes. 2020, 4:50-64. 10.1016/j.mayocpiqo.2019.10.008
21. Withbauer B, Busch C, Fraunberger P, et al.: Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med. 2005, 31:1696-1702. 10.1007/s00134-005-1910-0
22. Papanikolaou I, Makris D, Mpaka M, Palli E, Zygouris P, Zakythinos E: New insights into the mechanisms involved in B-type natriuretic peptide elevation and its prognostic value in septic patients. Crit Care. 2014, 18:R94. 10.1186/cc13864
23. Khoury J, Arow M, Elias A, et al.: The prognostic value of brain natriuretic peptide (BNP) in non-cardiac patients with sepsis, ultra-long follow-up. J Crit Care. 2017, 42:117-122. 10.1016/j.jcrc.2017.07.009
24. Ueda S, Nishio K, Akai Y, et al.: Prognostic value of increased plasma levels of brain natriuretic peptide in patients with septic shock. Shock. 2006, 26:154-159. 10.1097/01.shk.0000226266.99960.d0
25. McLean AS, Huang SJ, Hyams S, et al.: Prognostic values of B-type natriuretic peptide in severe sepsis and septic shock. Crit Care Med. 2007, 35:1019-1026. 10.1097/01.ccm.0000114827.95540.d8
26. Coutoiberto BH, Patel RR, Croyl BL, Barclay J, Hills GS: B-type natriuretic peptide and the prediction of outcome in patients admitted to intensive care. Anaesthesia. 2005, 60:16-21. 10.1111/j.1365-2044.2004.03972.x